ARTICLE | Clinical News
Simtuzumab: Development discontinued
December 6, 2016 7:58 PM UTC
Gilead said it discontinued development of subcutaneous simtuzumab for all indications after data from 3 double-blind, placebo-controlled, international Phase IIb trials showed a lack of efficacy. The...
BCIQ Target Profiles